REZUM is a minimally invasive surgical treatment which can be performed as a day case in patients with symptomatic benign prostatic hyperplasia. In Australia, REZUM is most commonly performed with in the private hospital sector which often has patients of different socio-economic status compared to the public hospital sector. The aim of our study was to assess the safety and efficacy of the REZUM procedure in a single Australian public hospital.

A retrospective study was performed in a single metropolitan Melbourne hospital looking at patients who underwent a REZUM procedure from January 2024 until December 2024. Outcomes included quality of life data (including ejaculatory and erectile function), international prostate symptoms score (IPSS), peak flow in uroflowmetry, post-micturition residual urine volume and reductions in medications to treat BPH. Baseline characteristics prior to REZUM treatment including prostate volume and prior prostate procedures. The number of REZUM treatments administered, along with treatment of the median lobe, any complications/re-operations and days until trial of void were recorded.

In total 22 patients underwent a REZUM procedure in 2024. All patients were discharged home on the same day with a catheter in situ for seven days. Overall quality of life was substantially improved in the majority of patients post operatively with 15 of 22 patients reporting improved LUTS. There was an improvement in IPSS from 22 to 12 at the three month follow up mark. Peak flow in uroflowmetry was measured at the three month follow up mark and noted to have increased from 8.7 to 13.68ml per second. Similarly, post void residual volume reduced from 44 to 27.9ml at three months.

REZUM therapy is a safe, effective and well tolerated procedure within the Australian public hospital system.